Advertisement
Advertisement
SYRE
Spyre Therapeutics, Inc. Common Stock
45.63
USDSponsored
+3.41
+8.08%
Mar 25, 15:59 UTC -4
Closed
After-Market
46.16
+0.53
+1.17%
SYRE Earnings Reports
Positive Surprise Ratio
SYRE beat 18 of 40 last estimates.
45%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.68
Implied change from Q4 25 (Revenue/ EPS)
--
/-2.86%
Implied change from Q1 25 (Revenue/ EPS)
--
/+13.33%
Spyre Therapeutics, Inc. Common Stock earnings per share and revenue
On Feb 19, 2026, SYRE reported earnings of -0.70 USD per share (EPS) for Q4 25, beating the estimate of -0.79 USD, resulting in a 11.43% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +14.28% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of -0.68 USD, with revenue projected to reach -- USD, implying an decrease of -2.86% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were Spyre Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Spyre Therapeutics, Inc. Common Stock reported EPS of -$0.70, beating estimates by 11.43%, and revenue of $0.00, 0% as expectations.
How did the market react to Spyre Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 14.28%, changed from $37.81 before the earnings release to $43.21 the day after.
When is Spyre Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Spyre Therapeutics, Inc. Common Stock's next earnings report?
Based on 11
analysts, Spyre Therapeutics, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement